Basic Transplantation Immunology

Surgical Clinics of North America

Volumn 86, Issue 5, 2006, Pages 1103-1125

  Hale, Douglas A ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BELATACEPT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CD8+ T LYMPHOCYTE; COMPLEMENT SYSTEM; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GRAFT REJECTION; GRANULOCYTE; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELL; HIGH THROUGHPUT SCREENING; HISTOCOMPATIBILITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; KIDNEY ALLOGRAFT; LIVER TRANSPLANTATION; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MONONUCLEAR CELL; NATURAL KILLER CELL; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYMOCYTE; TISSUE TYPING;

ANIMALS; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, NATURAL; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE;

EID: 33748291491     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2006.06.015     Document Type: Review

References (81)

1. Pancer Z., and Cooper M.D. The evolution of adaptive immunity. Annu Rev Immunol 24 (2006) 497-518
2. Rus H., Cudrici C., and Niculescu F. The role of the complement system in innate immunity. Immunol Res 33 2 (2005) 103-112
3. Young N.T. Immunobiology of natural killer lymphocytes in transplantation. Transplantation 78 1 (2004) 1-6
4. O'Connor G.M., Hart O.M., and Gardiner C.M. Putting the natural killer cell in its place. Immunology 117 1 (2006) 1-10
5. Croft M., and Dubey C. Accessory molecule and costimulation requirements for CD4 T cell response. Crit Rev Immunol 17 1 (1997) 89-118
6. O'Garra A., and Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 10 8 (2004) 801-805
7. Cassis L., Aiello S., and Noris M. Natural versus adaptive regulatory T cells. Contrib Nephrol 146 (2005) 121-131
8. + suppressor T cells regulate pathogen induced inflammation and disease. FEMS Immunol Med Microbiol 44 2 (2005) 121-127
9. + T cells and the control of autoimmune disease. Curr Opin Immunol 16 6 (2004) 695-701
10. Jiang S., Herrera O., and Lechler R.I. New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance. Curr Opin Immunol 16 5 (2004) 550-557
11. Illigens B.M., Yamada A., Fedoseyeva E.V., et al. The relative contribution of direct and indirect antigen recognition pathways to the alloresponse and graft rejection depends upon the nature of the transplant. Hum Immunol 63 10 (2002) 912-925
12. Land W.G. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation 79 5 (2005) 505-514
13. Andrade C.F., Waddell T.K., Keshavjee S., et al. Innate immunity and organ transplantation: the potential role of toll-like receptors. Am J Transplant 5 5 (2005) 969-975
14. Olszewski W.L. Innate immunity processes in organ allografting-their contribution to acute and chronic rejection. Ann Transplant 10 2 (2005) 5-9
15. Jeannet M., Pinn V.W., Flax M.H., et al. Humoral antibodies in renal allotransplantation in man. N Engl J Med 282 3 (1970) 111-117
16. McKenna R.M., Takemoto S.K., and Terasaki P.I. Anti-HLA antibodies after solid organ transplantation. Transplantation 69 3 (2000) 319-326
17. Terasaki P.I. Humoral theory of transplantation. Am J Transplant 3 6 (2003) 665-673
18. Pei R., Lee J., Chen T., et al. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol 60 12 (1999) 1293-1302
19. Feucht H.E., Felber E., Gokel M.J., et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 86 3 (1991) 464-470
20. Terasaki P.I., and Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 4 3 (2004) 438-443
21. Michaels P.J., Fishbein M.C., and Colvin R.B. Humoral rejection of human organ transplants. Springer Semin Immunopathol 25 2 (2003) 119-140
22. Michaels P.J., Espejo M.L., Kobashigawa J., et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 22 1 (2003) 58-69
23. Pelletier R.P., Hennessy P.K., Adams P.W., et al. Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation. Am J Transplant 2 2 (2002) 134-141
24. Adams A.B., Pearson T.C., and Larsen C.P. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev 196 (2003) 147-160
25. Taylor D.K., Neujahr D., and Turka L.A. Heterologous immunity and homeostatic proliferation as barriers to tolerance. Curr Opin Immunol 16 5 (2004) 558-564
26. Adams A.B., Williams M.A., Jones T.R., et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 111 12 (2003) 1887-1895
27. Pearl J.P., Parris J., Hale D.A., et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 5 3 (2005) 465-474
28. Sherman L.A., and Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol 11 (1993) 385-402
29. + T cells in human kidney transplant recipients. J Am Soc Nephrol 14 6 (2003) 1643-1651
30. Muthukumar T., Dadhania D., Ding R., et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 353 22 (2005) 2342-2351
31. Gregori S., Casorati M., Amuchastegui S., et al. Regulatory T cells induced by 1 alpha, 25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 167 4 (2001) 1945-1953
32. Zheng X.X., Sanchez-Fueyo A., Sho M., et al. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 19 4 (2003) 503-514
33. Calne R.Y. The rejection of renal homografts. Inhibition in dogs by 6-mercaptopurine. Lancet 1 (1960) 417-418
34. Heitman J., Movva N.R., and Hall M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253 5022 (1991) 905-909
35. Kuo C.J., Chung J., Fiorentino D.F., et al. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 358 6381 (1992) 70-73
36. Vincenti F., Larsen C., Durrbach A., et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353 8 (2005) 770-781
37. Bonnefoy-Berard N., and Revillard J.P. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 15 5 (1996) 435-442
38. Galante N.Z., Camara N.O., Kallas E.G., et al. Modulation of peripheral blood T-lymphocytes in kidney transplant recipients treated with low dose OKT3 therapy. Immunol Lett 91 1 (2004) 75-77
39. Starzl T.E., Marchioro T.L., Hutchinson D.E., et al. The clinical use of antilymphocyte globulin in renal homotransplantation. Transplantation 5 4 (1967) (Suppl):1100-5
40. Genestier L., Fournel S., Flacher M., et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 91 7 (1998) 2360-2368
41. Lenardo M., Chan K.M., Hornung F., et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 17 (1999) 221-253
42. Michallet M.C., Saltel F., Preville X., et al. Cathepsin-B-dependent apoptosis triggered by antithymocyte globulins: a novel mechanism of T-cell depletion. Blood 102 10 (2003) 3719-3726
43. Bonnefoy-Berard N., Vincent C., and Revillard J.P. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 51 3 (1991) 669-673
44. Rebellato L.M., Gross U., Verbanac K.M., et al. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 57 5 (1994) 685-694
45. Bourdage J.S., and Hamlin D.M. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 59 8 (1995) 1194-1200
46. Kirk A.D., Hale D.A., Mannon R.B., et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76 1 (2003) 120-129
47. Simpson D. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?. BioDrugs 17 3 (2003) 147-154
48. Hale G., Hoang T., Prospero T., et al. Removal of T cells from bone marrow for transplantation. Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes. Mol Biol Med 1 3 (1983) 305-319
49. Hale G., Bright S., Chumbley G., et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 62 4 (1983) 873-882
50. Dyer M.J., Hale G., Hayhoe F.G., et al. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73 6 (1989) 1431-1439
51. Calne R., Friend P., Moffatt S., et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 351 9117 (1998) 1701-1702
52. Prlic M., and Jameson S.C. Homeostatic expansion versus antigen-driven proliferation: common ends by different means?. Microbes Infect 4 5 (2002) 531-537
53. Wu Z., Bensinger S.J., Zhang J., et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 10 1 (2004) 87-92
54. Webster A.C., Playford E.G., Higgins G., et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77 2 (2004) 166-176
55. Adu D., Cockwell P., Ives N.J., et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 326 7393 (2003) 789
56. Li X.C., Roy-Chaudhury P., Hancock W.W., et al. IL-2 and IL-4 double knockout mice reject islet allografts: a role for novel T cell growth factors in allograft rejection. J Immunol 161 2 (1998) 890-896
57. Kircher B., Latzer K., Gastl G., et al. Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies. Clin Exp Immunol 134 3 (2003) 426-430
58. Bradley B.A. The role of HLA matching in transplantation. Immunol Lett 29 1-2 (1991) 55-59
59. Iwaki Y., Lau M., Cook D.J., et al. Crossmatching with B and T cells and flow cytometry. Clin Transpl 1 (1986) 277-284
60. Patel R., and Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280 14 (1969) 735-739
61. Meier-Kriesche H.U., Schold J.D., and Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?. Am J Transplant 4 8 (2004) 1289-1295
62. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4 3 (2004) 378-383
63. Lenschow D.J., Zeng Y., Thistlethwaite J.R., et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257 5071 (1992) 789-792
64. Kirk A.D., Harlan D.M., Armstrong N.N., et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 94 16 (1997) 8789-8794
65. Pearson T.C., Trambley J., Odom K., et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 74 7 (2002) 933-940
66. Vincenti F. Chronic induction. What's new in the pipeline. Contrib Nephrol 146 (2005) 22-29
67. Billingham R.E., Brent L., and Medawar P.B. Actively acquired tolerance of foreign cells. Nature 172 4379 (1953) 603-606
68. Kawai T., Cosimi A.B., Colvin R.B., et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 59 2 (1995) 256-262
69. Hamawi K., Magalhaes-Silverman M., and Bertolatus J.A. Outcomes of renal transplantation following bone marrow transplantation. Am J Transplant 3 3 (2003) 301-305
70. Buhler L.H., Spitzer T.R., Sykes M., et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 74 10 (2002) 1405-1409
71. Millan M.T., Shizuru J.A., Hoffmann P., et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 73 9 (2002) 1386-1391
72. Rao A.S., Dvorchik I., Dodson F., et al. Donor bone marrow infusion in liver recipients: effect on the occurrence of acute cellular rejection. Transplant Proc 33 1-2 (2001) 1352
73. Shapiro R., Rao A.S., Corry R.J., et al. Kidney transplantation with bone marrow augmentation: five-year outcomes. Transplant Proc 33 1-2 (2001) 1134-1135
74. Pham S.M., Rao A.S., Zeevi A., et al. Effects of donor bone marrow infusion in clinical lung transplantation. Ann Thorac Surg 69 2 (2000) 345-350
75. Corry R.J., Chakrabarti P.K., Shapiro R., et al. Simultaneous administration of adjuvant donor bone marrow in pancreas transplant recipients. Ann Surg 230 3 (1999) 372-379
76. Tryphonopoulos P., Tzakis A.G., Weppler D., et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am J Transplant 5 3 (2005) 608-613
77. Contreras J.L., Wang P.X., Eckhoff D.E., et al. Peritransplant tolerance induction with anti-CD3-immunotoxin: a matter of proinflammatory cytokine control. Transplantation 65 9 (1998) 1159-1169
78. Thomas J.M., Neville D.M., Contreras J.L., et al. Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts. Transplantation 64 1 (1997) 124-135
79. Thomas J.M., Eckhoff D.E., Contreras J.L., et al. Durable donor-specific T and B cell tolerance in rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and deoxyspergualin: absence of chronic allograft nephropathy. Transplantation 69 12 (2000) 2497-2503
80. McCurry K.R., Iacono A., Zeevi A., et al. Early outcomes in human lung transplantation with thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 130 2 (2005) 528-537
81. Watson C.J., Bradley J.A., Friend P.J., et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 5 6 (2005) 1347-1353